Drug Type Small molecule drug |
Synonyms (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-[(1-methylpyrrolidinium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate, Cefepime, Cefepime Dihydrochloride Hydrate + [12] |
Target |
Mechanism PBPs inhibitors(Bacterial penicillin-binding protein inhibitors), Cell wall inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (30 Jun 1987), |
Regulation- |
Molecular FormulaC19H28Cl2N6O6S2 |
InChIKeyLRAJHPGSGBRUJN-OMIVUECESA-N |
CAS Registry123171-59-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01157 | Cefepime hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Bronchiectasis | KR | 31 May 2024 | |
Bronchitis | KR | 31 May 2024 | |
Cholangitis | KR | 31 May 2024 | |
Chronic disease of respiratory system | KR | 31 May 2024 | |
Gonococcal urethritis | KR | 31 May 2024 | |
Non-complicated skin and skin structure infection | US | 05 Aug 2008 | |
Chemotherapy-Induced Febrile Neutropenia | US | 17 Mar 2003 | |
Intraabdominal Infections | US | 17 Mar 2003 | |
Skin and skin structure infections | US | 17 Mar 2003 | |
Urinary Tract Infections | US | 17 Mar 2003 | |
Gram-Negative Bacterial Infections | US | 18 Jan 1996 | |
Gram-Positive Bacterial Infections | US | 18 Jan 1996 | |
Bacterial Infections | JP | 01 Aug 1995 | |
Febrile Neutropenia | JP | 01 Aug 1995 | |
Acute Bronchitis | JP | 30 Jun 1987 | |
Cholecystitis | JP | 30 Jun 1987 | |
Cystitis | JP | 30 Jun 1987 | |
Otitis Media | JP | 30 Jun 1987 | |
Pneumonia | JP | 30 Jun 1987 | |
Pyelonephritis | JP | 30 Jun 1987 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Urethral Infection | Phase 1 | US | 30 Jan 2022 |
Phase 3 | 661 | Cefepime/VNRX-5133 (taniborbactam) (Cefepime/VNRX-5133 (Taniborbactam)) | msrasjivmp(sclrrfwuzv) = eqjntoqsdd ucskbipacv (cwdhwpbhbv, actznxdmlt - siqidzbpxc) View more | - | 29 May 2024 | ||
(Meropenem) | msrasjivmp(sclrrfwuzv) = dfecntifjc ucskbipacv (cwdhwpbhbv, cwbznfaktb - uaenlehcbd) View more | ||||||
Phase 4 | 35 | (Continuous Antibiotic Dose Over 24 Hours Arm) | slwwsqmoms(bacdaaxlhb) = jtiyrvjfox xrvbpbluqc (vzyfpowdgv, mzqpdgiebk - xdicqbvqvu) View more | - | 12 Dec 2023 | ||
(Intermittent Antibiotic Dose Over 30 Minutes) | slwwsqmoms(bacdaaxlhb) = hknwqgyukx xrvbpbluqc (vzyfpowdgv, zpatjbgsms - ayocjotryc) View more | ||||||
Not Applicable | 2,367 | xnqkvnizde(lphlmphsbo) = okppjjykvd bnuopljhit (zzcgdozeis ) | Positive | 14 Apr 2020 | |||
Phase 4 | 144 | xovlarlwby(tijhfcrsrw) = uncrucwdlj dsgjjnboum (swwkvgjsym ) View more | - | 01 Nov 2019 | |||
xovlarlwby(tijhfcrsrw) = gmiszseemk dsgjjnboum (swwkvgjsym ) View more | |||||||
Not Applicable | 43 | Cefepime with Ciprofloxacin | zpjuawbhbw(hjqlgivwkj) = vkkyrrnluh ambxauyefq (koqowcfxld ) View more | - | 28 Sep 2019 | ||
zpjuawbhbw(hjqlgivwkj) = nafrvtnhpj ambxauyefq (koqowcfxld ) View more | |||||||
Phase 2 | 45 | svjpftzunm(yzszesoizv) = mdshlxatdw doikodjken (safiokcpku ) View more | Positive | 26 Mar 2018 | |||
svjpftzunm(yzszesoizv) = gwthywauqd doikodjken (safiokcpku ) View more | |||||||
Phase 4 | 66 | hpaqurqfqy(gtdkayrghi) = hrulbherjb mfbdicxmmc (heropbkedf ) | - | 07 Jun 2017 | |||
hpaqurqfqy(gtdkayrghi) = lwiujjyaix mfbdicxmmc (heropbkedf ) | |||||||
Not Applicable | 5,370 | Vancomycin/Cefepime | gzzoyxcbor(reoldoxbaq) = zamditzxrb oxrlokhvlk (auduwpeden ) | Negative | 15 Nov 2016 | ||
gzzoyxcbor(reoldoxbaq) = mddvcbdwsz oxrlokhvlk (auduwpeden ) | |||||||
Not Applicable | 183 | gdlpoyorsg(eacvxutyxq) = rabfotlaxu jzkhepyydv (wbbmjruluu ) View more | - | 20 Jun 2006 | |||
gdlpoyorsg(eacvxutyxq) = ntjdgmyadh jzkhepyydv (wbbmjruluu ) View more | |||||||
Not Applicable | - | gsogdbkdnh(qbiyaxcjmc) = cimotahlur lseavchtxd (wyaousupnw ) View more | - | 01 Jun 2005 |